 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Itraconazole and Amphotericin B To Treat Fungal Infections in Patients with Cancer Who Are Receiving Chemotherapy
18 September 2001 | Volume 135 Issue 6 | Page S39
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "Intravenous and Oral Itraconazole versus Intravenous Amphotericin B Deoxycholate as Empirical Antifungal Therapy for Persistent Fever in Neutropenic Patients with Cancer Who Are Receiving Broad-Spectrum Antibacterial Therapy. A Randomized, Controlled Trial." It is in the 18 September 2001 issue of Annals of Internal Medicine (volume 135, pages 412-422). The authors are M Boogaerts, DJ Winston, EJ Bow, G Garber, AC Reboli, AP Schwarer, N Novitzky, A Boehme, E Chwetzoff, K De Beule, and the Itraconazole Neutropenia Study Group.
What is the problem and what is known about it so far?
When patients with cancer receive chemotherapy (drugs used to kill cancer cells), normal cells in the bone marrow are often temporarily damaged or destroyed. Since the bone marrow produces cells that fight infection (white blood cells, or leukocytes), chemotherapy often increases susceptibility to infection. These infections are usually due to bacteria or fungi. It is often difficult to determine which organism has caused infection. Fungi are difficult to treat and often cause fatal complications, unless treatment is started early or before infection starts. Patients with low white blood cell counts due to chemotherapy and suspected fungal infection usually receive amphotericin B. Although 43% to 72% of these patients improve while taking this drug, bad side effects occur in 35% to 82%. An effective, less toxic, alternative treatment would be helpful.
Why did the researchers do this particular study?
To determine whether itraconazole is as good as amphotericin B in treating possible fungal infections in patients with cancer who are receiving chemotherapy.
Who was studied?
384 patients with cancers of the blood (from 10 countries) who had received chemotherapy. Patients had to have fever, a low white blood cell count, and at least 3 days of previous antibiotic therapy.
How was the study done?
Patients were assigned to receive amphotericin B or itraconazole. Amphotericin B was given intravenously. Itraconazole was first given intravenously and then by mouth. Treatment outcome was considered good if fever disappeared and the white blood cell count became high enough to ward off infection. Treatment failure occurred if the patient had progressive fungal infection, died of any cause after 3 days of therapy, had continued fever, or needed to change therapy because of poor response or side effects. The two drugs were judged equivalent if the difference in response to treatment was no larger than 15%.
What did the researchers find?
Treatment was successful in 47% of patients receiving itraconazole and 38% receiving amphotericin B. Eleven percent of patients taking itraconazole and 14% of those taking amphotericin B died. Significantly fewer patients who took itraconazole (19%) than those who took amphotericin B (38%) had to stop therapy because it had toxic effects. However, 19 patients taking itraconazole but only 1 patient taking amphotericin B had to change medications because of continuing fever. Itraconazole had fewer side effects than amphotericin B.
What are the limitations of the study?
Three quarters of patients in both groups had received oral antifungal drugs to prevent fungal infections before the study began. Both the researchers and the patients knew which drug was being given, and this may have affected some judgments. Since specific fungus infections were not confirmed by the laboratory, the researchers cannot be certain that one drug is more effective than the other in treating a particular fungal infection.
What are the implications of the study?
Itraconazole appears as effective as amphotericin B in cancer patients at risk for fungal infections during chemotherapy. It also has fewer side effects and can be given orally after initial intravenous therapy.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  K. Oshima, Y. Kanda, Y. Asano-Mori, N. Nishimoto, S. Arai, S. Nagai, H. Sato, T. Watanabe, N. Hosoya, K. Izutsu, et al. Presumptive treatment strategy for aspergillosis in allogeneic haematopoietic stem cell transplant recipients J. Antimicrob. Chemother., August 1, 2007; 60(2): 350 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Blyth, P. Palasanthiran, and T. A. O'Brien Antifungal Therapy in Children With Invasive Fungal Infections: A Systematic Review Pediatrics, April 1, 2007; 119(4): 772 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Wingard, H. L. Leather, C. A. Wood, W. C. Gerth, R. J. Lupinacci, M. L. Berger, and E. C. Mansley Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever Am. J. Health Syst. Pharm., March 15, 2007; 64(6): 637 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Enoch, H. A. Ludlam, and N. M. Brown Invasive fungal infections: a review of epidemiology and management options. J. Med. Microbiol., July 1, 2006; 55(Pt 7): 809 - 818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Glasmacher, O. Cornely, A. J. Ullmann, U. Wedding, H. Bodenstein, H. Wandt, C. Boewer, R. Pasold, H.-H. Wolf, M. Hanel, et al. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia J. Antimicrob. Chemother., February 1, 2006; 57(2): 317 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Glasmacher, A. Prentice, M. Gorschluter, S. Engelhart, C. Hahn, B. Djulbegovic, and I. G.H. Schmidt-Wolf In Reply: J. Clin. Oncol., December 20, 2005; 23(36): 9429 - 9432. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Girmenia, M. L. Moleti, A. Micozzi, A. P. Iori, W. Barberi, R. Foa, and P. Martino Breakthrough Candida krusei Fungemia during Fluconazole Prophylaxis followed by Breakthrough Zygomycosis during Caspofungin Therapy in a Patient with Severe Aplastic Anemia Who Underwent Stem Cell Transplantation J. Clin. Microbiol., October 1, 2005; 43(10): 5395 - 5396. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pfaller, L. Boyken, R. J. Hollis, S. A. Messer, S. Tendolkar, and D. J. Diekema In Vitro Susceptibilities of Clinical Isolates of Candida Species, Cryptococcus neoformans, and Aspergillus Species to Itraconazole: Global Survey of 9,359 Isolates Tested by Clinical and Laboratory Standards Institute Broth Microdilution Methods J. Clin. Microbiol., August 1, 2005; 43(8): 3807 - 3810. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Walsh, H. Teppler, G. R. Donowitz, J. A. Maertens, L. R. Baden, A. Dmoszynska, O. A. Cornely, M. R. Bourque, R. J. Lupinacci, C. A. Sable, et al. Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and Neutropenia N. Engl. J. Med., September 30, 2004; 351(14): 1391 - 1402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Johnson, C. MacDougall, L. Ostrosky-Zeichner, J. R. Perfect, and J. H. Rex Combination Antifungal Therapy Antimicrob. Agents Chemother., March 1, 2004; 48(3): 693 - 715. [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Marr, F. Crippa, W. Leisenring, M. Hoyle, M. Boeckh, S. A. Balajee, W. G. Nichols, B. Musher, and L. Corey Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants Blood, February 15, 2004; 103(4): 1527 - 1533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. G. Nichols Management of Infectious Complications in the Hematopoietic Stem Cell Transplant Recipient J Intensive Care Med, November 1, 2003; 18(6): 295 - 312. [Abstract] [PDF]
|
|
|
|
 |
|
 D. J. Winston, R. T. Maziarz, P. H. Chandrasekar, H. M. Lazarus, M. Goldman, J. L. Blumer, G. J. Leitz, and M. C. Territo Intravenous and Oral Itraconazole versus Intravenous and Oral Fluconazole for Long-Term Antifungal Prophylaxis in Allogeneic Hematopoietic Stem-Cell Transplant Recipients: A Multicenter, Randomized Trial Ann Intern Med, May 6, 2003; 138(9): 705 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A Pacetti and S. P Gelone Caspofungin Acetate for Treatment of Invasive Fungal Infections Ann. Pharmacother., January 1, 2003; 37(1): 90 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Flansbaum and J. M. Huddleston Update in Hospital Medicine Ann Intern Med, November 19, 2002; 137(10): 814 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Verweij, D. T. A. Te Dorsthorst, A. J. M. M. Rijs, H. G. De Vries-Hospers, and J. F. G. M. Meis Nationwide Survey of In Vitro Activities of Itraconazole and Voriconazole against Clinical Aspergillus fumigatus Isolates Cultured between 1945 and 1998 J. Clin. Microbiol., July 1, 2002; 40(7): 2648 - 2650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. Vitale, J. W. Mouton, J. Afeltra, J. F. G. M. Meis, and P. E. Verweij Method for Measuring Postantifungal Effect in Aspergillus Species Antimicrob. Agents Chemother., June 1, 2002; 46(6): 1960 - 1965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Johnson, A. J. Ullmann, C. P. Heussel, O. A. Cornely, A. Apisarnthanarak, J. R. Little, P. Tebas, T. J. Walsh, P. G. Pappas, and D. J. Winston Voriconazole versus Liposomal Amphotericin B for Empirical Antifungal Therapy N. Engl. J. Med., May 30, 2002; 346(22): 1745 - 1747. [Full Text] [PDF]
|
|
|
|
 |
|
 ADDITIONAL ARTICLES ABSTRACTED IN ACP JOURNAL CLUB Evid. Based Med., March 1, 2002; 7(2): 35 - 35. [Full Text] [PDF]
|
|
|
|
|
|
G. Maschmeyer New antifungal agents--treatment standards are beginning to grow old J. Antimicrob. Chemother., February 1, 2002; 49(2): 239 - 241. [Full Text] [PDF]
|
|
|
|
|
|
T. J. Walsh, P. Pappas, D. J. Winston, H. M. Lazarus, F. Petersen, J. Raffalli, S. Yanovich, P. Stiff, R. Greenberg, G. Donowitz, et al. Voriconazole Compared with Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Neutropenia and Persistent Fever N. Engl. J. Med., January 24, 2002; 346(4): 225 - 234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Marr Empirical Antifungal Therapy -- New Options, New Tradeoffs N. Engl. J. Med., January 24, 2002; 346(4): 278 - 280. [Full Text] [PDF]
|
|
|
|
 |
|
 Amphotericin B or Itraconazole for the Febrile Neutropenic Patient? Journal Watch Infectious Diseases, October 4, 2001; 2001(1004): 3 - 3. [Full Text]
|
|
|
|
 |
|
 Itraconazole for Fever in Neutropenic Cancer Patients Journal Watch (General), October 2, 2001; 2001(1002): 2 - 2. [Full Text]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
